InnoCare Pharma logo

InnoCare Pharma(SEHK) 9969

Market CapHK$22.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+27%
5 Year-39%
1 Year-15%
1 Month-21%
HK$12.20
-2.09%
-0.26Today
InnoCare Pharma last closing stock price
MetricPriceDate
Last closeHKD 12.202026-10-14
InnoCare Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.7%HKD 13.512026-10-07
1 month-21.34%HKD 15.512026-09-14
3 month-16.95%HKD 14.692026-07-16
Year to date-0.81%HKD 12.302025-12-31
1 year-14.63%HKD 14.292025-10-14
3 year+101.99%HKD 6.042023-10-13
5 year-39.15%HKD 20.052021-10-15
Since inception+27.01%HKD 9.812020-03-23

InnoCare Pharma Financials at a Glance

Market Cap

HK$22.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥2.75B

Net Income (TTM)

CN¥906.94M

EPS (TTM)

HK$0.58

P/E Ratio

21.55

Dividend

HK$0.00

Beta (Volatility)

-0.13 (Low)

Price

HK$12.20

Volume

7,510,700

Open

HK$12.24

Previous Close

HK$12.46

Daily Range

HK$12.01 - HK$12.40

52-Week Range

HK$9.65 - HK$16.20

Estimated Earnings Date

Oct 27, 2026

9969 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InnoCare Pharma

InnoCare Pharma Limited is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. The company is recognized for its lead product, Orelabrutinib, a BTK inhibitor that addresses various forms of lymphomas and autoimmune conditions.

Products and Services
  • Orelabrutinib, a BTK inhibitor for multiple cancers and autoimmune diseases
  • ICP-192, a pan-FGFR inhibitor in Phase I/II trials for solid tumors
  • ICP-723, a pan-TRK inhibitor targeting neurotrophic tyrosine receptor kinase fusion
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials
  • Recent revenue growth of 15.6% quarter-over-quarter
  • Significant market potential in oncology and autoimmune sectors
Financial Highlights
  • Q2 2026 net income of CNY 139.9 million, up from CNY 104.9 million in Q1
  • TTM revenue of CNY 2.1 billion, reflecting a robust growth trajectory
  • Current ratio of 4.21 indicates strong liquidity position
InnoCare Pharma Limited has established itself as a key player in the biotechnology sector, particularly in the treatment of complex diseases. The company's innovative approach and strong pipeline of products position it well for future growth. Recent financial performance highlights a positive trend, with increasing revenues and net income, suggesting effective management and operational efficiency. The strong liquidity ratios further enhance the company's financial stability, making it an attractive option for potential investors interested in the biopharmaceutical industry.
AI Generated • Sep 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,259

CEO

Jisong Cui, PhD

Website

www.innocarepharma.com

Headquarters

Beijing, BE 102206, CN

9969 Financials

Key Financial Metrics (TTM)

Gross Margin

89.85%

Operating Margin

28.21%

Net Income Margin

32.93%

Return on Equity

12.35%

Return on Capital

4.72%

Return on Assets

8.09%

Earnings Yield

4.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$22.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.77B

Volume

7.51M

Avg. Volume

8.36M

Financials (TTM)

Gross Profit

CN¥2.48B

Operating Income

CN¥777.01M

EBITDA

CN¥837.02M

Operating Cash Flow

CN¥320.62M

Capital Expenditure

-CN¥84.60M

Free Cash Flow

CN¥236.02M

Cash & ST Invst.

CN¥8.37B

Total Debt

CN¥2.23B

InnoCare Pharma Performance Analysis

InnoCare Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 722,475,424-42.5%
20232023-12-31CNY 809,708,87612.1%
20242024-12-31CNY 1,083,259,88333.8%
20252025-12-31CNY 2,557,895,103136.1%
InnoCare Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-309.6%
Q42025-12-31223.4%
Q12026-03-31-57.8%
Q22026-06-3015.7%
InnoCare Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.581225.2%
20232023-12-31CNY -0.40-32.3%
20242024-12-31CNY -0.27-31.5%
20252025-12-31CNY 0.40N/A
InnoCare Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3050.8%
Q42025-12-312151.3%
Q12026-03-31-85.1%
Q22026-06-3033.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥605.84M

+73.0%

Gross Profit

CN¥526.73M

+70.2%

Gross Margin

86.94%

N/A

Market Cap

HK$22.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$15.86M

N/A

Employees

1,388

N/A

Net Income

CN¥139.94M

+391.2%

EBITDA

CN¥102.72M

+230.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥8.37B

+15.5%

Total Debt

CN¥2.23B

+45.1%

Accounts Receivable

CN¥563.41M

+43.6%

Inventory

CN¥198.50M

+68.6%

Long Term Debt

CN¥992.90M

-27.2%

Short Term Debt

CN¥1.24B

+611.1%

Return on Assets

8.09%

N/A

Return on Invested Capital

8.60%

N/A

Free Cash Flow

CN¥77.84M

+160.7%

Operating Cash Flow

CN¥97.24M

+182.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
INTCIntel
$98.12-4.56%

Questions About 9969

What is the current price of InnoCare Pharma?

InnoCare Pharma is trading at HK$12.20 per share.

What is the 52-week range for InnoCare Pharma?

Over the past 52 weeks, InnoCare Pharma has traded between HK$9.65 and HK$16.20.

How much debt does InnoCare Pharma have?

As of the most recent reporting period, InnoCare Pharma reported total debt of CN¥2.58B.

How much cash does InnoCare Pharma have on hand?

InnoCare Pharma reported CN¥7.31B in cash and cash equivalents in its most recent financial results.

What is InnoCare Pharma’s dividend yield?

InnoCare Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services